Showing results (51-60 of 3,350) with videos related to

Sort By:
Pageof 335
The Lancet. Oncology|July 20, 2020
S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trialYoon-Koo Kang, Keisho Chin, Hyun Cheol Chung, et al.
The Lancet. Oncology|September 4, 2025
De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trialDaniel Ma, Katharine Price, Eric Moore, et al.
The Lancet. Oncology|July 8, 2015
Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-OncologyKhê Hoang-Xuan, Eric Bessell, Jacoline Bromberg, et al.
The Lancet. Oncology|July 8, 2015
Polypharmacy in patients with advanced cancer and the role of medication discontinuationThomas W LeBlanc, Michael J McNeil, Arif H Kamal, et al.
The Lancet. Oncology|July 11, 2015
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trialJean-Charles Soria, Yi-Long Wu, Kazuhiko Nakagawa, et al.
The Lancet. Oncology|July 20, 2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trialClaus Rödel, Ullrich Graeven, Rainer Fietkau, et al.
The Lancet. Oncology|June 21, 2015
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trialsJürg Bernhard, Weixiu Luo, Karin Ribi, et al.
The Lancet. Oncology|February 4, 2018
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 studyGiuseppe Giaccone, Chul Kim, Jillian Thompson, et al.
The Lancet. Oncology|February 7, 2018
Effect of early and systematic integration of palliative care in patients with advanced cancer: a randomised controlled trialGaëlle Vanbutsele, Koen Pardon, Simon Van Belle, et al.
The Lancet. Oncology|March 17, 2018
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 studyMarina Chiara Garassino, Byoung-Chul Cho, Joo-Hang Kim, et al.
Pageof 335